Cilnidipine significantly improved HOMA-R in non-diabetics, and triglycerides, eGFR, and urinary albumin/creatinine ratio in diabetics compared to amlodipine.
Observational (n=77)
Does cilnidipine improve glucose metabolism, lipid metabolism, and renal function compared to amlodipine in patients with hypertension and type II diabetes mellitus?
Cilnidipine, an L/N-type calcium channel blocker, provides superior renoprotective and metabolic benefits compared to amlodipine in hypertensive patients with type II diabetes.
It has been proved that cilnidipine has N-type calcium channels inhibitory activity as well as L-type calcium channels and inhibits excessive release of norepinephrine from the sympathetic nerve ending. This study was undertaken to compare the efficacy of amlodipine (an inhibitor of L-type calcium channels) and cilnidipine (an inhibitor of both L-type and N-type calcium channels) in patients with hypertension and type II diabetes mellitus. Seventy-seven hypertensive patients were divided into two groups according to presence/absence of type II diabetes mellitus. In these two groups of patients, the effects of amlodipine and cilnidipine on glucose and lipid metabolism and renal function were compared. As for glucose and lipid metabolism, homeostasis model assessment insulin resistance (HOMA-R) level in the non-diabetic group and triglyceride in the diabetes group were significantly lower with cilnidipine than with amlodipine. As regards renal function in the diabetic group, estimated glomerular filtration rate (eGFR) was significantly higher and urinary albumin/creatinine ratio was significantly lower with cilnidipine than with amlodipine. Cilnidipine which inhibits N-type calcium channels is more useful for patients with hypertension and diabetes mellitus from its effects on glucose and lipid metabolism and renal function.
Masuda et al. (Wed,) conducted a observational in Hypertension with or without Type II Diabetes Mellitus (n=77). Cilnidipine vs. Amlodipine was evaluated on Glucose and lipid metabolism (HOMA-R, triglyceride) and renal function (eGFR, urinary albumin/creatinine ratio). Cilnidipine significantly improved HOMA-R in non-diabetics, and triglycerides, eGFR, and urinary albumin/creatinine ratio in diabetics compared to amlodipine.